COMMUNIQUÉS West-GlobeNewswire

Dentsply Sirona Reports Preliminary Fourth Quarter and Full Year 2018 Results
01/03/2019
Reported Q4 revenues of $1,059.7 million, down 2.9%, and down 0.1% on an internal sales growth basis. [1] Q4 2018 US GAAP EPS of $0.01 vs. a loss of $2.85 in Q4 2017. Q4 2018 Non-US GAAP EPS of $0.58 compared with Non- [...]
Digirad Corporation Reports Financial Results for the Fourth Quarter and Twelve Months Ended December 31, 2018
01/03/2019
Performs within guidance for Revenue and Free Cash Flow for 2018 Pays down $10 million in debt during 2018, including $4 million in Q4 2018 SUWANEE, Ga., March 01, 2019 (GLOBE NEWSWIRE) -- Digirad Corporation (Nasdaq: [...]
Oasmia Pharmaceutical AB (publ)
01/03/2019
Interim report for the period May 2018 – January 2019 THIRD QUARTER November 1, 2018 – January 31, 2019 Consolidated net sales amounted to TSEK 1,427 compared to TSEK 656 in the third quarter the previous year Operating [...]
DBV Technologies to Attend Upcoming Investor Conferences
01/03/2019
Montrouge, France, March 1, 2019 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, [...]
DBV Technologies invitée à présenter lors de prochaines conférences Investisseurs
01/03/2019
Montrouge, France, le 1 mars (7h30 CET), 2019 DBV Technologies invitée à présenter lors de prochaines conférences Investisseurs DBV Technologies (Euronext: DBV – ISIN : FR0010417345 - Nasdaq Stock Market : DBVT), une [...]
Kiadis Pharma to present at upcoming investor conferences in March 2019
01/03/2019
Kiadis Pharma to present at upcoming investor conferences in March 2019 Amsterdam, The Netherlands, March 1, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a [...]
Orphazyme announces Annual Report 2018
01/03/2019
Orphazyme A/S Company announcement No. 04/2019 Company Registration No. 32266355 Copenhagen, Denmark, March 1, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for [...]
Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliatin
01/03/2019
SHANGHAI, China, March 01, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, [...]
Bone Therapeutics announces 2018 full year results
01/03/2019
Regulated Information Significant progress across all areas of the business Positioned to move the clinical pipeline into late-stage development Proprietary, optimised commercial production process fully operational [...]
Bone Therapeutics publie ses résultats annuels 2018
01/03/2019
Information réglementée Avancées significatives dans tous les secteurs d’activité En position pour faire passer le portefeuille clinique à un stade de développement avancé Procédés de production commerciale brevetés, [...]
CannaPharmaRx Announces the Acquisition of a Minority Interest in GN Ventures, a Canadian Cannabis Producer, and the Appointment of Dominic Colvin as CEO and Chairman of the Board
01/03/2019
Company Continues to acquire Cannabis Grow Capacity in Canada IRVINE, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- CannaPharmaRx, Inc. (OTC Pink Sheets: “CPMD”) announced today it has completed the acquisition of a [...]
Revive Therapeutics Announces Results for the Three and Six Months Ended December 31, 2018
01/03/2019
TORONTO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) (‘Revive’ or the ‘Company’) , a specialty cannabis company focused on the research, development and [...]
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia
01/03/2019
COPENHAGEN, Denmark, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today [...]
Extendicare Announces 2018 Year End Results and Leadership Changes
01/03/2019
MARKHAM, Ontario, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the fourth quarter and year ended December 31, 2018. Results are presented in [...]
Management Cease Trade Order Update
01/03/2019
HALIFAX, Nova Scotia, Feb. 28, 2019 (GLOBE NEWSWIRE) -- MedMira Inc. (TSXV: MIR) (“MedMira” or the “Company”) provides an update with respect to the previously announced management cease trade order (the “MCTO”) issued [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/03/2019
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2019, that were previously [...]
MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports
01/03/2019
LA JOLLA, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Lexicon Pharmaceuticals Announces Poster Presentations at the 16th Annual ENETS Conference
28/02/2019
THE WOODLANDS, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from two posters highlighting XERMELO ® (telotristat ethyl) will be presented at the [...]
Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results
28/02/2019
SAN FRANCISCO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases [...]

Pages